ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Primary drug resistance in antiretroviral-naive injection drug users.
 PMID: 19111493       2009       International journal of infectious diseases
Abstract: RESULTS: Genotypic drug resistance was uncommon, and was only identified in six (4.7%) cases, all in the RT gene (L100I, K103N, Y181C, M184V, Y188L, and T215D).


  Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
 PMID: 19119321       2009       PloS one
Method: NVP-R was defined by mutations present at the following amino acid sites: L100I, K101E/P, K103N/S, V106A/M, V108I, Y181C/I/V, Y188C/L/H, or G190A/S/E based on recommendations from International AIDS Society-USA Drug Resistance Mutations and Stanford University drug-resistance database.


  Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
 PMID: 19235860       2009       Journal of medical virology
Abstract: Most of the discordance was due to the differential weights attributed to Y181C/V, L100I, and K101P in the two weighted algorithms.


  Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
 PMID: 19277127       2009       PloS one
Result: Other polymorphisms (L100I, L100S, V106A) were observed in individual sequences but were not associated with G190A mutation.


  Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
 PMID: 19281225       2009       Journal of medicinal chemistry
Abstract: Against the mutant L100I, K103N, and Y181C RT HIV-1 strains in CEM cells, sulfones 3, 4, 19, 27, and 31 were comparable to EFV.
Abstract: The binding mode of 19 was not affected by the L100I mutation and was consistent with the interactions reported for the WT strain.


  Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
 PMID: 19320243       2009       Antiviral therapy
Abstract: These included V90I, A98G, L100I, K1O1E/P/Q, K103H/N/S/T, V106A/I/M, V108I, E138G/K/Q, V179D/E/F/G/I, Y181C/I/V, Y188C/H/L, V189I, G190A/C/E/Q/S, H221Y, P225H, F227C/L, M230I/L, P236L, K238N/T and Y318F


  Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants.
 PMID: 19403922       2009       Journal of biomolecular screening
Abstract: A lead optimization library consisting of 800 HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) was screened in parallel against 4 clinically relevant variants of HIV-1 RT (Wt, L100I, Y181C, and K103N) using a surface plasmon resonance-based biosensor.


  [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
 PMID: 19545051       2009       Yao xue xue bao
Abstract: All nine recombinant VSVG/HIV-mut pseudovirions (VSVG/HIV-wt, VSVG/HIV(-K103N), VSVG/HIV(-Y181C), VSVG/HIV(-L100I,K103N), VSVG/HIV(-Y188L), VSVG/HIV(-K103N,Y181C), VSVG/HIV(-K103N,P225H), VSVG/HIV(-K103N,Y188L), VSVG/HIV(-K103N,G109A) and VSVG/HIV(-K103N,V108I)) had high efficient infectivity.


  In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
 PMID: 19552593       2009       AIDS research and human retroviruses
Table: L100I


  Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
 PMID: 19732174       2009       HIV medicine
Abstract: The presence of major IAS-USA mutations (L100I, K101E/H/P and Y181C/I/V) reduced the treatment response at week 24.



Browser Board

 Co-occurred Entities




   Filtrator